HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 2 matching records:

Displaying record number 59429

HXB2 Location  Gag(166-175)   Gag Epitope Map
View variants at this location
Epitope PEVIPMFSAL   Epitope Alignment
Variants
PEVIPMFaAL   observed variant
PEVIPMFmAL   observed variant
PEVIPMFtAL   observed variant
Epitope Name Gag166-175
Species (MHC/HLA human(C*03:04)

Variant Details

Showing all: 3 variant(s).


Variant ID.  4040
Epitope Seq.  PEVIPMFSAL
Variant Seq.  PEVIPMFaAL
Mutations S/A
Epitope Location S8A
HXB2 Location S173A
Mutation Type OV: observed variant
Method Sequence
Note The S173A variant at position 8, PEVIPMFaAL (34-8A), was present at a frequency of 2.4%


Variant ID.  4041
Epitope Seq.  PEVIPMFSAL
Variant Seq.  PEVIPMFmAL
Mutations S/M
Epitope Location S8M
HXB2 Location S173M
Mutation Type OV: observed variant
Method Sequence
Note The S173M variant at position 8, PEVIPMFmAL (34-8M), was present at a frequency of 1.3%.


Variant ID.  4042
Epitope Seq.  PEVIPMFSAL
Variant Seq.  PEVIPMFtAL
Mutations S/T
Epitope Location S8T
HXB2 Location S173T
Mutation Type OV: observed variant
Method Sequence
Note The S173T variant at position 8, PEVIPMFtAL (34-8T), was present at a frequency of 39.1%.

References

vanTeijlingen2014 Nienke H. van Teijlingen, Angelique Hölzemer, Christian Körner, Wilfredo F. García-Beltrán, Jamie L. Schafer, Lena Fadda, Todd J. Suscovich, Christian Brander, Mary Carrington, David T Evans, Debbie van Baarle, and Marcus Altfeld. Sequence Variations in HIV-1 p24 Gag-Derived Epitopes Can Alter Binding of KIR2DL2 to HLA-C*03:04 and Modulate Primary Natural Killer Cell Function. AIDS, 28(10):1399-1408, 19 Jun 2014. PubMed ID: 24785948. Show all entries for this paper.


Displaying record number 59431

HXB2 Location  Gag(295-304)   Gag Epitope Map
View variants at this location
Epitope DYVDRFFKTL   Epitope Alignment
Variants
DYVDRFFKvL   escape documented in this paper
DYVDRFFKaL   escape documented in this paper
DYVDRFFKcL   escape documented in this paper
DYVDRFFKiL   escape documented in this paper
Epitope Name Gag295-304
Species (MHC/HLA human(C*03:04)

Variant Details

Showing all: 4 variant(s).


Variant ID.  4036
Epitope Seq.  DYVDRFFKTL
Variant Seq.  DYVDRFFKvL
Mutations T/V
Epitope Location T9V
HXB2 Location T303V
Mutation Type E: escape documented in this paper
Method Other
Note The T303V variant at position 9, DYVDRFFKvL (163-9V), was present at a frequency of 5% and also strongly binds the inhibitory NK cell receptor, KIR2DL2, evading NK-cell mediated killing.


Variant ID.  4037
Epitope Seq.  DYVDRFFKTL
Variant Seq.  DYVDRFFKaL
Mutations T/A
Epitope Location T9A
HXB2 Location T303A
Mutation Type E: escape documented in this paper
Method Other
Note The T303A variant at position 9, DYVDRFFKaL (163-9A), was present at a frequency of 2.4% and also binds the inhibitory NK cell receptor, KIR2DL2.


Variant ID.  4038
Epitope Seq.  DYVDRFFKTL
Variant Seq.  DYVDRFFKcL
Mutations T/C
Epitope Location T9C
HXB2 Location T303C
Mutation Type E: escape documented in this paper
Method Other
Note The T303C variant at position 9, DYVDRFFKcL (163-9C), was present at a frequency of 1.5% and also binds the inhibitory NK cell receptor, KIR2DL2.


Variant ID.  4039
Epitope Seq.  DYVDRFFKTL
Variant Seq.  DYVDRFFKiL
Mutations T/I
Epitope Location T9I
HXB2 Location T303I
Mutation Type E: escape documented in this paper
Method Other
Note The T303I variant at position 9, DYVDRFFKiL (163-9I), was present at a frequency of 1% and also binds the inhibitory NK cell receptor, KIR2DL2.

References

vanTeijlingen2014 Nienke H. van Teijlingen, Angelique Hölzemer, Christian Körner, Wilfredo F. García-Beltrán, Jamie L. Schafer, Lena Fadda, Todd J. Suscovich, Christian Brander, Mary Carrington, David T Evans, Debbie van Baarle, and Marcus Altfeld. Sequence Variations in HIV-1 p24 Gag-Derived Epitopes Can Alter Binding of KIR2DL2 to HLA-C*03:04 and Modulate Primary Natural Killer Cell Function. AIDS, 28(10):1399-1408, 19 Jun 2014. PubMed ID: 24785948. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health